Abstract: There is provided a material comprising a multi-block thermogelling polymer, said multi-block thermogelling polymer comprising a hydrophilic polymer block; a thermosensitive polymer block; and a hydrophobic polymer block, wherein the hydrophilic polymer block, the thermosensitive polymer block and the hydrophobic polymer block are chemically coupled together by at least one of urethane/carbamate, carbonate, ester linkages or combinations thereof, and wherein the material is suitable for use as a vitreous substitute. Also provided are a method of preparing said material and a synthetic vitreous humour or part thereof comprising said material.

Abstract: A hand-held sized ocular and neurological screening device, system and method, the screening device comprising an eyepiece and a hand-held housing, the housing comprising a tubular stimulus chamber defining a light stimulus channel, wherein an illumination source is configured to provide light stimulus towards an opening through the light stimulus channel and an operational chamber comprising an infrared camera positioned outside the stimulus channel and inclined towards the opening, the infrared camera is configured to capture images of the pupils and eye movements through the opening without interfering with the light stimulus and a controller configured to receive the captured images from the infrared camera. The hand-held sized device can include a clip-on fixture for fixing the device onto a table, a desktop, or any portable ophthalmic apparatus.

Abstract: Ultrasound imaging methods for identifying an anatomical feature of a spine are described. In an embodiment, the method comprises: receiving a transverse ultrasound image of a portion of the spine; extracting features of the portion of the spine from the image based on a distinct pattern associated with the anatomical feature of the spine; identifying a midline of the portion of the spine in the image; extracting midline features using pixel intensity values of the image; and identifying, based on a combination of the extracted features of the portion of the spine and the extracted midline features, the anatomical feature in the image. In another embodiment, the method comprises: receiving a paramedian sagittal ultrasound image of a portion of the spine; identifying morphological features of the image; and determining if the portion of the spine includes a sacrum using a Support Vector Machine classifier.

Abstract: The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.

Abstract: Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: A pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein, use of the pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases, and use of the pharmaceutical composition for immunomodulation.

Abstract: Disclosed is an optical cylinder of a corneal prosthesis comprising: a) an optical cylinder comprising a solid polymer, and b) a plurality of nanoparticles forming a substantially uniform layer on a circumference of the solid polymer surface of the optical cylinder. Also disclosed are methods of surface treatment of optical cylinders of corneal prostheses, and corneal prostheses thereof.

Abstract: An IL-11 binding receptor capable of binding to IL-11 and inhibiting IL-11 mediated signalling is disclosed. Also disclosed are compositions comprising the IL-11 binding receptor and methods using the IL-11 binding receptor.

Abstract: The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent, L is a linker unit; —is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.

Abstract: The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2,4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2,4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one a-lysine residue for an ?-lysine residue, and the modified peptides display antimicrobial activity.

Abstract: Various embodiments relate to a stent assembly comprising a stent; a swellable coating disposed on at least a portion of an exterior surface of the stent; optionally, a carrier dispersed in the swellable coating and/or disposed on at least a portion of an exterior surface of the stent; and an active agent comprised in at least one of the swellable coating or the carrier, if present. Use of the stent assembly as a ureteric stent, and method of preparing a stent assembly are also provided.

Abstract: Method of detecting phosphorylation at Threonine 166 of a Rubicon protein to identify a subject having a disease associated with Leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease and compounds and methods for treating the same.

Abstract: Disclosed herein are methods treating a subject suffering from peritoneal carcinomatosis with a PAI-1 inhibitor, wherein the method comprises determining the concentration of “plasminogen activator inhibitor 1” (PAI-1) and determining the level of phosphorylation of “signal transducer and activator of transcript 3” (STAT3) in a sample obtained from the subject. Also disclosed herein are methods of detecting or determining susceptibility of a subject suffering from peritoneal carcinomatosis to treatment with a PAI-1 inhibitor.

Abstract: Methods of treating and preventing kidney injury through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: Methods of treating and preventing hepatotoxicity through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.

Abstract: Disclosed is a method for training a neural network to quantify the vessel calibre of retina fundus images. The method involves receiving a plurality of fundus images; pre-processing the fundus images to normalise images features of the fundus images; and training a multi-layer neural network, the neural network comprising of a convolutional unit, multiple dense blocks alternating with transition units for down-sampling image features determined by the neural network, and a fully-connected unit, wherein each dense block comprises a series of cAdd units packed with multiple convolutions, and each transition layer comprises a convolution with pooling.

Abstract: The present invention relates to compounds comprising formula I: Amino Acid Sequence-(L)n-DMARD wherein the amino acid sequence comprises QKRAAYDQYGHAAFE-NH2 (SEQ ID NO: 1), DMARD is a disease modifying antirheumatic agent L is a linker unit,—is a covalent bond and n is 0 or 1 and methods of using the compound for treatment of autoimmune diseases. In a preferred embodiment the DMARD is selected from Chloroquine and Hydroxychloroquine.

Abstract: The present invention refers to a method of predicting susceptibility of a subject suffering from cancer to a treatment with an anti-cancer drug, wherein the method comprises detecting the presence or absence of a genetic alteration in a long non-coding RNA (IncRNA) that resides in an antisense strand of an oncogene, wherein the genetic alteration disrupts expression of the oncogene, and wherein the subject is predicted to be more susceptible to the treatment if the genetic alteration is present. In particular, the genetic alteration is a silent G>A mutation at Q787Q of the oncogene epidermal growth factor receptor (EGFR). Also disclosed herein is a method of treating a subject suffering from cancer, who was shown to have a genetic alteration in IncRNA that resides in an antisense strand of an oncogene.

Abstract: An IL-11 binding receptor capable of binding to IL-11 and inhibiting IL-11 mediated signalling is disclosed. Also disclosed are compositions comprising the IL-11 binding receptor and methods using the IL-11 binding receptor.

Abstract: This disclosure provides methods of a method of treating a retinal angiogenic in a subject comprising administering an effective amount of an Angio-3 peptide.